Latest stories on TRAX
TRAX Maintained by Guggenheim -- Price Target Raised to $110
GuruFocus63 · neutralanalyst
First Tracks Biotherapeutics price target raised to $110 from $100 at Guggenheim
The Fly64 · neutralanalyst
First Tracks Biotherapeutics, Inc. GAAP EPS of -$0.88 beats by $0.03
Seeking Alpha58 · neutralearnings
First Tracks Biotherapeutics reports Q3 EPS (88c), consensus (89c)
The Fly52 · neutralearnings
First Tracks Biotherapeutics, Inc. (TRAX) files 8-K
SEC 8-K50 · neutralgeneral
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire53 · neutralproduct/pr
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire64 · neutralearnings
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Insider64 · neutralearnings
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
Business Insider53 · neutralproduct/pr
First Tracks Biotherapeutics, Inc. (TRAX) files 8-K
SEC 8-K53 · neutralgeneral
First Tracks Biotherapeutics, Inc. (TRAX) files 8-K
SEC 8-K50 · neutralgeneral
First Tracks Biotherapeutics announces $200M private placement
The Fly26 · bearishgeneral
First Tracks Biotherapeutics Announces $200 Million Private Placement
StockTitan26 · bearishgeneral
First Tracks Biotherapeutics Announces $200 Million Private Placement
GlobeNewswire24 · bearishgeneral
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
Seeking Alpha64 · neutralanalyst
At a glance: stocks gapping up premarket
Seeking Alpha58 · neutralgeneral
TRAX slides even as ANB033 posts statistically significant protection in a 14-day gluten challenge
October 13, 2026
MarketChameleon64 · neutralproduct/pr
First Tracks Biotherapeutics, Inc. (TRAX) files 8-K
SEC 8-K50 · neutralgeneral
Canaccord raises First Tracks Biotherapeutics price target on trial data
Investing.com Analyst Ratings64 · neutralanalyst
First Tracks: ANB033 Delivers, But Cohort 2 Must Follow Through
Seeking Alpha58 · neutralanalyst
First Tracks Biotherapeutics price target raised to $60 from $50 at Canaccord
The Fly64 · neutralanalyst
First Tracks Biotherapeutics price target raised to $70 from $62 at Wells Fargo
The Fly63 · neutralanalyst
TRAX jumps ahead of Oct. 12 webcast as First Tracks tees up Phase 1b ANB033 celiac data
MarketChameleon63 · neutralproduct/pr
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%
Investors.com74 · bullishproduct/pr